CHML Antibody

What is CHML protein and what cellular functions does it regulate?

CHML (choroideremia-like) protein plays a critical role in intracellular vesicle trafficking by facilitating the recycling of Rab proteins, particularly Rab14. Through direct interaction with Rab14, CHML escorts this GTPase to membrane compartments, supporting its constant recycling within the cell. This process is essential for maintaining proper vesicular transport, which impacts multiple cellular functions including cell migration, invasion, and metastasis. In hepatocellular carcinoma (HCC), CHML has been shown to promote cancer progression by enhancing the metastatic potential of tumor cells through its interaction with Rab14-positive vesicles .

How are CHML antibodies typically generated for research applications?

CHML antibodies are typically generated using standard monoclonal or polyclonal antibody production techniques. For monoclonal antibodies, the process follows the hybridoma technology where mice or other host animals are immunized with CHML protein or peptide fragments. B cells from these animals are then fused with myeloma cells to create hybridomas that produce CHML-specific antibodies. These antibodies undergo rigorous screening for specificity, affinity, and cross-reactivity before being purified for research use. Modern approaches may also involve phage display techniques where antibody libraries are screened against CHML to identify high-affinity binders . The quality of CHML antibodies is critically dependent on the immunogen design, which typically targets unique epitopes within the CHML protein to ensure specificity and minimize cross-reactivity with related proteins.

What are the different types of CHML antibodies available for research, and how should one select the appropriate antibody?

Researchers can choose from several types of CHML antibodies, each with specific applications:

When selecting a CHML antibody, researchers should consider: 1) The specific application (Western blot, IHC, etc.), 2) The species compatibility (human, mouse, etc.), 3) The epitope location and its conservation across species, 4) Validation data demonstrating specificity in relevant experimental systems. For functional studies involving CHML-Rab14 interactions, antibodies targeting the specific domains involved in this interaction would be most appropriate .

How can CHML antibodies be used to investigate the relationship between CHML expression and cancer progression?

CHML antibodies serve as essential tools for investigating the role of CHML in cancer progression through multiple experimental approaches. For quantitative analysis of CHML expression, immunohistochemistry (IHC) with specific CHML antibodies can be performed on tissue microarrays (TMAs) containing paired tumor and normal tissues. This approach allows researchers to correlate CHML expression levels with clinicopathological parameters, as demonstrated in HCC studies where high CHML expression was associated with serious ascites, satellite nodules, and early recurrence .

Western blot analysis using CHML antibodies provides a complementary approach to quantify CHML protein levels in cell lines and tissue samples. This method has revealed that CHML expression is elevated in HCC tissues compared to matched normal tissues, with further increases observed in portal vein tumor thrombus (PVTT) tissues, suggesting a correlation between CHML expression and metastatic potential .

For functional studies, CHML antibodies can be used in combination with RNA interference approaches to validate knockdown efficiency when investigating how CHML depletion affects cancer cell behaviors such as migration, invasion, and metastasis. Research has shown that CHML knockdown significantly reduces migration and invasion capabilities of HCC cells, providing direct evidence for its role in promoting metastasis .

What methodological approaches using CHML antibodies can reveal the mechanism of CHML in cancer metastasis?

To elucidate the mechanisms by which CHML promotes cancer metastasis, researchers can employ several methodological approaches using CHML antibodies:

• Co-immunoprecipitation (Co-IP) assays using CHML antibodies have revealed that CHML directly interacts with Rab14, a key regulator of vesicular trafficking. This interaction can be confirmed using both overexpression systems and endogenous proteins in relevant cancer cell lines .

• Immunofluorescence microscopy with CHML antibodies enables visualization of CHML subcellular localization and its co-localization with Rab14 and other vesicular markers. This approach helps map the intracellular trafficking pathways regulated by CHML.

• Proximity ligation assays (PLA) using CHML antibodies can provide higher resolution detection of protein-protein interactions in situ, offering spatial information about where CHML-Rab14 interactions occur within the cell.

• For analyzing the functional consequences of CHML-mediated Rab14 recycling, researchers can combine CHML antibodies with markers of vesicular transport. Studies have shown that CHML escorts Rab14 to membrane compartments, supporting the constant recycling of Rab14, which is crucial for metastasis .

• GST pull-down assays with purified components, detected using CHML antibodies, can determine direct protein interactions and the specific domains mediating these interactions, as demonstrated for CHML and Rab14 .

How can CHML expression patterns detected by antibodies correlate with clinical outcomes in cancer patients?

CHML expression patterns detected by antibodies have demonstrated significant correlations with clinical outcomes in cancer patients, particularly in HCC. To establish these correlations, researchers typically employ the following methodological approaches:

What are the optimal protocols for using CHML antibodies in different experimental techniques?

Optimizing protocols for CHML antibodies across different experimental techniques requires careful consideration of multiple factors. Below are methodology-specific recommendations:

For Western Blotting:

• Sample preparation: Use RIPA buffer with protease inhibitors for complete protein extraction

• Recommended dilution: 1:1000-1:2000 for most CHML antibodies

• Blocking: 5% non-fat milk or BSA for 1 hour at room temperature

• Membrane washing: 3-5 times with TBST after primary and secondary antibody incubations

• Validation controls: Include positive control (HCC cell lines with high CHML expression such as CSQT-2 or LM3) and negative control (CHML knockdown cells)

For Immunoprecipitation:

• Lysate preparation: Use mild lysis buffers (e.g., NP-40 buffer) to preserve protein-protein interactions

• Antibody amount: 2-5 μg per 500 μg of total protein

• Pre-clearing: Incubate lysate with protein A/G beads before adding antibody to reduce non-specific binding

• Incubation time: Overnight at 4°C with gentle rotation

• This technique has successfully identified CHML-Rab14 interactions in multiple cell lines

For Immunohistochemistry:

• Antigen retrieval: Citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes

• Antibody dilution: 1:100-1:200 for formalin-fixed paraffin-embedded tissues

• Incubation time: 1-2 hours at room temperature or overnight at 4°C

• Detection system: HRP-conjugated secondary antibody with DAB substrate

• Counterstaining: Hematoxylin for nuclear visualization

• Scoring: Implement standardized scoring systems based on staining intensity and percentage of positive cells

For Immunofluorescence:

• Fixation: 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilization: 0.1% Triton X-100 for 10 minutes

• Blocking: 5% normal serum in PBS for 1 hour

• Primary antibody dilution: 1:100-1:500 overnight at 4°C

• Co-staining: Combine with Rab14 antibodies to visualize co-localization

How can researchers validate the specificity of CHML antibodies to ensure reliable experimental results?

Validating CHML antibody specificity is crucial for generating reliable research data. Comprehensive validation strategies include:

• Genetic knockout/knockdown controls: Compare antibody signals between wild-type cells and CHML knockdown cells created using shRNA or CRISPR-Cas9 technology. A specific antibody should show significantly reduced or absent signal in knockdown/knockout samples as demonstrated in CHML knockdown experiments in HCC cell lines .

• Overexpression controls: Test antibody reactivity in cells transiently transfected with CHML expression vectors. Specific antibodies should show increased signal intensity proportional to overexpression levels compared to empty vector controls.

• Peptide competition assays: Pre-incubate CHML antibody with the immunizing peptide before application to the sample. Specific binding should be blocked, resulting in signal reduction or elimination.

• Cross-reactivity assessment: Test the antibody against related proteins (like REP1, which has similar function to CHML) to ensure it doesn't cross-react with similar epitopes.

• Multi-technique concordance: Verify that the antibody produces consistent results across different applications (Western blot, IHC, IF, etc.) with appropriate positive and negative controls.

• Reproducibility testing: Confirm consistent results across different lots of the same antibody and between different antibodies targeting distinct CHML epitopes.

• Mass spectrometry validation: Perform immunoprecipitation followed by mass spectrometry to confirm that the antibody is pulling down CHML and identify any non-specific interactions .

What advanced techniques can be combined with CHML antibodies to study CHML-Rab14 interactions in living cells?

Advanced techniques that can be combined with CHML antibodies to study CHML-Rab14 interactions in living cells include:

• Förster Resonance Energy Transfer (FRET): By labeling CHML and Rab14 with appropriate fluorophore pairs, researchers can detect direct molecular interactions in living cells with nanometer resolution. This technique requires specialized microscopy equipment but provides dynamic information about protein interactions.

• Fluorescence Recovery After Photobleaching (FRAP): This technique can assess the mobility and exchange rate of fluorescently-tagged CHML and Rab14 proteins, providing insights into their dynamic association with membranes and vesicles. FRAP experiments have been valuable in understanding how CHML affects Rab14 mobility between cytosolic and membrane compartments.

• Live-cell imaging with photoswitchable probes: Using antibody fragments (Fab) conjugated to photoswitchable fluorophores allows tracking of endogenous CHML in living cells with minimal perturbation to normal cellular function.

• Bimolecular Fluorescence Complementation (BiFC): This technique involves fusing complementary fragments of a fluorescent protein to CHML and Rab14. When the proteins interact, the fragments reconstitute the fluorescent protein, enabling visualization of the interaction sites within the cell.

• Optogenetic approaches: Light-inducible protein interaction systems can be used to temporarily disrupt or enhance CHML-Rab14 interactions, allowing researchers to study the immediate consequences of these interactions on vesicular trafficking and cell behavior.

• Super-resolution microscopy: Techniques like STORM or PALM, when combined with appropriate antibodies or tags, can resolve CHML-Rab14 interactions at the nanoscale level, providing spatial information about these interactions in relation to vesicular compartments .

What are common issues encountered when using CHML antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with CHML antibodies. Here are common issues and their methodological solutions:

When resolving weak signals specifically for CHML detection, researchers should consider that CHML expression varies across cell types, with higher expression observed in metastatic HCC cell lines like CSQT-2 and LM3 compared to less aggressive lines like PLC/PRF/5 and YY-8103 . Using appropriate positive controls based on this expression pattern can help calibrate experimental conditions.

How can researchers interpret contradictory results when studying CHML with different antibodies?

When faced with contradictory results using different CHML antibodies, researchers should implement a systematic approach to resolve these discrepancies:

• Epitope mapping analysis: Different antibodies may target distinct epitopes on the CHML protein. Determine which epitopes each antibody recognizes and assess whether these regions might be differentially accessible in various experimental conditions or cellular contexts. For instance, antibodies targeting the REP domain of CHML may yield different results compared to those targeting other regions, particularly when studying CHML-Rab14 interactions .

• Validation in multiple systems: Validate contradictory findings across multiple cell lines and tissue samples. For CHML research, compare results in both high-expressing (CSQT-2, LM3) and low-expressing (PLC/PRF/5, YY-8103) cell lines to identify potential cell-type specific effects .

• Complementary techniques: Employ multiple detection methods beyond antibody-based approaches. Combine results from antibody-based methods with mRNA expression analysis (RT-qPCR), mass spectrometry, or CRISPR-based functional studies to develop a coherent understanding of CHML biology.

• Cross-validation with tagged proteins: Use epitope-tagged CHML constructs (HA, FLAG, GFP) alongside antibody detection to confirm results with independent detection methods. This approach was successfully used to confirm CHML-Rab14 interactions .

• Knockdown/knockout controls: Generate CHML knockdown or knockout cells and test all antibodies against these genetic controls. This verification step is critical for determining which antibody most accurately reflects CHML biology.

• Consult literature: Compare results with published studies on CHML. Literature reports indicate CHML is upregulated in HCC and promotes metastasis through Rab14 recycling .

• Antibody characterization: Consider requesting detailed characterization data from manufacturers or performing additional validation experiments to understand the binding properties of each antibody.

What are the most reliable approaches to quantify CHML expression levels using antibody-based methods?

Reliable quantification of CHML expression using antibody-based methods requires rigorous standardization and appropriate controls. The following approaches provide the most accurate measurements:

• Western blot with densitometry analysis: For quantitative Western blot analysis of CHML, researchers should:

  • Use a loading control (β-actin, GAPDH) with similar abundance to CHML

  • Include a standard curve of recombinant CHML protein at known concentrations

  • Ensure signal falls within the linear range of detection

  • Perform at least three biological replicates

  • Use specialized software (ImageJ, Image Lab) for densitometry analysis

  • Report results as CHML/loading control ratio

  This approach was successfully used to quantify CHML upregulation in 21 out of 24 paired HCC tissue samples compared to matched normal tissues .

• Quantitative immunohistochemistry (IHC): For tissue analysis, implement:

  • Standardized staining protocol with automated platforms

  • Multi-tier scoring system (0, 1+, 2+, 3+) based on staining intensity

  • Calculate H-score (percentage of positive cells × intensity)

  • Include positive and negative tissue controls in each batch

  • Employ digital pathology platforms for objective quantification

  • Have at least two independent pathologists score samples

  This method was used to assess CHML expression in a 297-specimen tissue microarray, revealing significant correlations with clinical outcomes .

• Flow cytometry: For cell-based quantification:

  • Use permeabilization protocols optimized for intracellular antigens

  • Include isotype controls to set background thresholds

  • Report mean fluorescence intensity (MFI) rather than percent positive

  • Validate with CHML-overexpressing and knockdown controls

  • Use quantitative beads to convert MFI to molecules of equivalent soluble fluorochrome (MESF)

• ELISA/AlphaLISA: For high-throughput quantification:

  • Develop sandwich assays using two antibodies targeting different CHML epitopes

  • Include standard curves with recombinant CHML

  • Validate assay linearity, sensitivity, and precision

  • Optimize sample dilution to ensure measurements fall within the linear range

These quantitative approaches should be validated using genetic controls (knockdown/overexpression) to ensure specificity and accuracy when measuring CHML expression levels .

How might new antibody engineering approaches improve CHML antibody specificity and utility?

Emerging antibody engineering technologies offer promising avenues to enhance CHML antibody specificity and expand their research applications:

• Computational design of antibody specificity: Recent advances in computational modeling can predict antibody-antigen interactions and design antibodies with customized specificity profiles. By applying machine learning algorithms trained on phage display experiments, researchers can develop CHML antibodies with either highly specific binding to particular epitopes or cross-specificity for related proteins as needed. This approach has been validated experimentally for the generation of antibodies with novel binding profiles not present in the training data .

• Single-domain antibodies (nanobodies): These smaller antibody fragments derived from camelid heavy-chain antibodies offer superior tissue penetration and access to epitopes that might be inaccessible to conventional antibodies. Applied to CHML research, nanobodies could provide better resolution of CHML subcellular localization in complex tissues and improved detection of CHML-Rab14 interactions in confined cellular compartments.

• Bispecific antibodies: Engineering antibodies that simultaneously bind to CHML and Rab14 could provide more precise tools for studying their interactions. Such bispecific antibodies would enable selective detection of CHML-Rab14 complexes without detecting the individual proteins when they are not interacting.

• Recombinant antibody fragments: Fab, scFv, or Fab2 fragments offer advantages in certain applications due to their smaller size and lack of Fc regions. For CHML research, these fragments might provide better tissue penetration in IHC applications and reduced background in immunoprecipitation experiments.

• Antibody conjugates with proximity labeling enzymes: Conjugating CHML antibodies with enzymes like APEX2, BioID, or TurboID would enable proximity-dependent labeling of proteins that interact with CHML in living cells, providing a comprehensive interactome beyond the known Rab14 interaction .

What novel experimental approaches combining CHML antibodies with emerging technologies could advance our understanding of CHML function?

Integration of CHML antibodies with cutting-edge technologies offers unprecedented opportunities to dissect CHML function in complex biological systems:

• Spatial transcriptomics and in situ sequencing with antibody detection: Combining CHML antibody staining with spatial transcriptomics would reveal how CHML protein expression correlates with gene expression patterns in tissue microenvironments. This approach could identify previously unknown regulatory networks associated with CHML in cancer metastasis.

• Mass cytometry (CyTOF): Employing metal-conjugated CHML antibodies in CyTOF analysis would enable simultaneous detection of CHML alongside dozens of other proteins in single cells. This technique could reveal how CHML expression correlates with cell phenotypes in heterogeneous cancer populations.

• Intravital microscopy with labeled antibody fragments: Using fluorescently labeled CHML antibody fragments for intravital microscopy would allow real-time visualization of CHML dynamics during cancer metastasis in living organisms, providing insights into its in vivo role.

• Cryo-electron tomography with immunogold labeling: This technique would enable visualization of CHML-Rab14 interactions at near-atomic resolution in their native cellular context, revealing structural details of how CHML escorted Rab14 to membranes .

• Antibody-based proximity proteomics: Methods like APEX-mediated proximity labeling, when used with CHML antibodies, could map the dynamic protein interactions of CHML in different cellular compartments, potentially identifying additional partners beyond Rab14.

• Single-molecule tracking: Using quantum dot-conjugated antibody fragments would enable tracking of individual CHML molecules in living cells, revealing their diffusion characteristics, residence times at membranes, and interaction dynamics with Rab14.

• Optogenetic manipulation combined with antibody detection: Developing systems to optically control CHML function, followed by antibody-based detection of consequences, would allow researchers to establish direct cause-effect relationships in CHML-mediated cellular processes .

How might CHML antibodies contribute to the development of targeted cancer therapies?

CHML antibodies hold significant potential for contributing to targeted cancer therapies, particularly for hepatocellular carcinoma where CHML overexpression is associated with poor prognosis and early recurrence . Several promising translational applications include:

• Companion diagnostics: CHML antibodies could be developed into diagnostic tools to identify patients with CHML-overexpressing tumors who might benefit from targeted therapies. Standardized IHC protocols using validated CHML antibodies could stratify patients based on expression levels, similar to HER2 testing in breast cancer.

• Antibody-drug conjugates (ADCs): Given the elevated expression of CHML in HCC and its association with metastasis, CHML-targeted ADCs could deliver cytotoxic payloads specifically to cancer cells with high CHML expression. The internalization of CHML following antibody binding would need to be characterized to assess the feasibility of this approach.

• Blocking antibodies: If extracellular epitopes of CHML are identified or if delivery systems for intracellular antibodies are developed, therapeutic antibodies could potentially disrupt CHML-Rab14 interactions. Given that this interaction promotes metastasis in HCC, its inhibition could reduce cancer spread.

• CAR-T cell therapy: If CHML protein is expressed on the cell surface under certain conditions, CHML antibody-derived single-chain variable fragments (scFvs) could be incorporated into chimeric antigen receptors for adoptive cell therapy.

• Theranostic applications: Dual-function antibodies conjugated to both imaging agents and therapeutic molecules could enable simultaneous diagnosis and treatment of CHML-overexpressing tumors.

• Targeting the CHML-Rab14 pathway: Even if direct targeting of CHML proves challenging, antibodies against CHML could guide the development of small molecule inhibitors or peptide mimetics that disrupt CHML-Rab14 interactions, potentially reducing metastatic potential in HCC .

These approaches would require extensive validation, including confirmation that inhibition of CHML activity in vivo reduces tumor progression, as suggested by the prolonged survival observed in mouse models with CHML knockdown .

What are the most reliable sources of validated CHML antibodies for specific research applications?

When selecting validated CHML antibodies for research, consider the following sources based on application needs:

For all applications, antibodies should be evaluated based on the following criteria:

• Published validation data in peer-reviewed literature

• Verification using genetic controls (knockdown/knockout)

• Lot-to-lot consistency testing

• Species reactivity appropriate for your experimental system

• Epitope information and potential for interference with protein function

Custom antibody development services may be considered for specialized applications where commercial antibodies are inadequate or unavailable.

What databases and bioinformatic tools can help researchers analyze CHML expression data generated using antibodies?

Several databases and bioinformatic tools can assist researchers in analyzing CHML expression data:

• Cancer Genomics Resources:

  • The Cancer Genome Atlas (TCGA): Contains RNA-seq and clinical data showing correlations between CHML expression and survival in liver cancer as referenced in research studies

  • cBioPortal: Enables visualization of CHML alterations across cancer types and correlation with clinical outcomes

  • Human Protein Atlas: Provides antibody-based CHML protein expression data across normal and cancer tissues

• Proteomics Databases:

  • ProteomicsDB: Contains mass spectrometry-based data on CHML expression across tissues and cell lines

  • Peptide Atlas: Provides information on CHML peptides detected in various proteomics experiments

  • PRIDE Archive: Repository of proteomics data that may include CHML detection in various studies

• Analysis Tools:

  • R packages (limma, DESeq2): For differential expression analysis of CHML in various conditions

  • GSEA (Gene Set Enrichment Analysis): To identify pathways associated with CHML expression patterns

  • STRING and BioGRID: For analyzing protein-protein interaction networks involving CHML, particularly with Rab proteins

  • Cell Profiler: For quantitative analysis of immunofluorescence images showing CHML localization

  • QuPath: Open-source software for digital pathology and quantitative analysis of CHML IHC staining

• GEO Datasets:

  • Gene Expression Omnibus datasets like GSE74656, which has been used to analyze CHML expression patterns in non-cancerous tissues, primary HCCs, and PVTT tissues

• Sequence Analysis Tools:

  • Clustal Omega: For alignment of CHML sequences across species to identify conserved domains

  • PyMOL or Chimera: For structural visualization of CHML and its interaction with Rab14 based on published structures